Loading...
Loading...
RLYB| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 11.6M |
| Operating I/L | -11.6M |
| Other Income/Expense | 0.6M |
| Interest Income | 0.8M |
| Pretax | -11.0M |
| Income Tax Expense | -0.4M |
| Net Income/Loss | -11.0M |
Rallybio Corporation is a clinical-stage biotechnology company focused on discovering, developing, and delivering therapies for severe and rare diseases. Their lead product candidate, RLYB212, is a monoclonal anti-HPA-1a antibody in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company also has a pipeline including RLYB211, RLYB114, and RLYB116 targeting various rare diseases. Additionally, Rallybio has a collaboration with Exscientia for the development of small molecule therapeutics for rare diseases.
